Prana Biotechnology Investor Presentation

June 27, 2018 Kerry Rowe

1_Prana Biotechnology Investor Presentation_2018-0627 final

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

May 3, 2019May 9, 2019

Prana provides regulatory update for PBT2 for the treatment of Huntington disease

November 2, 2016

Prana’s PBT2 Reverses Memory Loss in Normal Aging

November 27, 2013

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Therapies
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Prana Biotechnology Investor Presentation

Related Posts

Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting

Prana provides regulatory update for PBT2 for the treatment of Huntington disease

Prana’s PBT2 Reverses Memory Loss in Normal Aging